Hepion Gets FDA Feedback on Planned Gambling Disorder Drug Study
The FDA's Division of Psychiatry issued written responses to Hepion's Type B pre-IND meeting request, addressing the regulatory pathway, nonclinical package and planned Phase 2 study design. The agency said nonclinical and manufacturing data already on file under an IND may be cross-referenced.